<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804865</url>
  </required_header>
  <id_info>
    <org_study_id>WP-2019-02</org_study_id>
    <nct_id>NCT04804865</nct_id>
  </id_info>
  <brief_title>Secondary Prognostic Index in RefrActory Lymphoma</brief_title>
  <acronym>SPiRAL</acronym>
  <official_title>Secondary Prognostic Index in RefrActory Diffuse Large B Cells Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weprom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weprom</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      60% of patients with diffuse large B cell lymphoma are healed after first-line treatment&#xD;
      which whatever the age. For the remaining 40% of patients (relapses and primary&#xD;
      refractories):&#xD;
&#xD;
        -  38% of patients will be cured with a 2nd line including an autologous haematopoietic&#xD;
           cell transplantation for those under 65 years.&#xD;
&#xD;
        -  for older patients who are not eligible for a autograft: only 70% of patients will be&#xD;
           able to receive 2nd line treatment with rates response less than 50%.&#xD;
&#xD;
        -  the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years.&#xD;
           Actually, no standard of chemotherapy is offered to relapsed or refractory patients&#xD;
           after 2 therapeutic lines. Subsequent lines lead to hospitalizations for infectious&#xD;
           complications or transfusions without clear clinical benefit with often an impacted&#xD;
           quality of life.&#xD;
&#xD;
      Palliative care is rarely offered as part of the treatment overall load.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time between the date of relapse or no response observed (after 2 lines of chemotherapy in young patients and one line for elderly patients) and the date of death regardless of the cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median response time after each line</measure>
    <time_frame>5 years</time_frame>
    <description>Time between the date when the first response criterion is observed (partial or complete response) and the date when the recurrence or progression is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival since diagnosis and after each line of treatment received</measure>
    <time_frame>5 years</time_frame>
    <description>Time between the date of diagnosis and the date of the first event observed, then between the date of the first administration of each line of treatment administered and the date of onset of the first event observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the intensity dose of chemotherapy received</measure>
    <time_frame>6 month</time_frame>
    <description>Total amount of chemotherapy administered relative to the theoretical dose calculated according to the patient's body surface area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Cumulative Illness Rating Scale for comorbidities score in patients over 65 years old</measure>
    <time_frame>6 month</time_frame>
    <description>The cumulative illness rating scale for comorbidity score in elderly patients will be calculated according to the table proposed by Salvi et al. in 2008 (values :0 to 56; higher scores mean a worse outcome).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>population</arm_group_label>
    <description>The population includes adult patients.&#xD;
Patients died from refractory or relapsed diffuse large-cell lymphoma.&#xD;
Patients &lt;65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.&#xD;
Patients &gt;65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prognostic assessment</intervention_name>
    <description>determination of a prognostic score with 3 clinical and 5 biological parameters.</description>
    <arm_group_label>population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population includes adult patients, who have died with refractory or relapsed diffuse&#xD;
        large-cell lymphoma. Patients &lt;65 years of age eligible for an autologous transplant should&#xD;
        have relapsed after the autologous transplant.&#xD;
&#xD;
        Patients&gt; 65 years of age or not eligible after an autologous transplant must have received&#xD;
        at least one RCHOP-type treatment line (2 cycles).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  died of diffuse large B cell lymphoma&#xD;
&#xD;
          -  Refractory or relapsing after 2 treatment lines for young patients (RCHOP then&#xD;
             recovery with platinum salts and autograft) and one line for elderly patients (RCHOP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with HIV infection&#xD;
&#xD;
          -  solid tumor treated less than 5 years ago with the exception of skin carcinoma or&#xD;
             carcinoma in situ of the uterine cervix treated locally&#xD;
&#xD;
          -  inclusion in a therapeutic trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katell LE DU, MD</last_name>
    <role>Study Director</role>
    <affiliation>Weprom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magali BALAVOINE</last_name>
    <phone>241682940</phone>
    <phone_ext>+33</phone_ext>
    <email>m.balavoine@weprom.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katell LE DU, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Victor Hugo / Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katell LE DÛ, MD</last_name>
      <phone>0243391300</phone>
      <phone_ext>0033</phone_ext>
      <email>k.ledu@cjb72.org</email>
    </contact>
    <investigator>
      <last_name>Katell LE DÛ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge BOLOGNA</last_name>
      <email>s.bologna@oncog.fr</email>
    </contact>
    <investigator>
      <last_name>Serge BOLOGNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prognostic score</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

